Attention Deficit Hyperactivity Disorder

GPTKB entity

Statements (52)
Predicate Object
gptkbp:instanceOf neurological disorder
gptkbp:abbreviation ADHD
gptkbp:affects adults
children
gptkbp:associatedWith social problems
occupational impairment
academic difficulties
executive function deficits
gptkbp:characterizedBy hyperactivity
impulsivity
inattention
gptkbp:commonMedication gptkb:atomoxetine
gptkb:methylphenidate
amphetamine
gptkbp:comorbidity gptkb:depression
gptkb:conduct_disorder
gptkb:oppositional_defiant_disorder
learning disabilities
anxiety disorders
gptkbp:controversy medication use
overdiagnosis
gptkbp:diagnosedBy gptkb:DSM-5_criteria
clinical assessment
behavioral observation
gptkbp:DSM-5_code 314.00
gptkbp:firstDescribed 1902
gptkbp:gender more common in males
https://www.w3.org/2000/01/rdf-schema#label Attention Deficit Hyperactivity Disorder
gptkbp:ICD-10_code gptkb:F90
gptkbp:includedIn gptkb:DSM-5
gptkb:ICD-10
gptkbp:longTermOutcome may persist into adulthood
gptkbp:notableContributor gptkb:Sir_George_Frederic_Still
gptkbp:prevalence 2.5% of adults worldwide
5% of children worldwide
gptkbp:relatedTo ADD (Attention Deficit Disorder)
gptkbp:riskFactor genetics
premature birth
prenatal exposure to tobacco
prenatal exposure to alcohol
gptkbp:subspecies combined presentation
predominantly hyperactive-impulsive
predominantly inattentive
gptkbp:supportersGroup gptkb:ADDA
CHADD
gptkbp:symptomOnset before age 12
gptkbp:treatment gptkb:psychotherapy
behavioral therapy
psychoeducation
stimulant medication
gptkbp:bfsParent gptkb:Attention_Deficit
gptkbp:bfsLayer 5